title: Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease.
abstract: Immunization with amyloid beta (Abeta) peptides or passive immunization with antibodies against Abeta has been reported to reduce plaque burden, neuritic dystrophy, early Tau pathology, microgliosis as well as reversing learning and memory deficits. This has created a central paradox: how does vaccination in peripheral tissues reduce plaque burden in the brain? No single explanation for these phenomena has yet been presented. To reconcile these observations, we demonstrate that the integrity of the blood-brain barrier (BBB), a structural barrier between the brain and the blood, is compromised in Tg2576 Alzheimer disease (AD) model mice. We immunized Tg2576 mice with Abeta before and after the onset of AD-type neuropathology and observed that BBB permeability, amyloid burden, and microgliosis are decreased in immunized mice. It is concluded that the integrity of the BBB is disrupted in AD mice, and after Abeta immunization the immune system clears Abeta from sources in the brain as it would in peripheral organs lacking barriers. Once Abeta is removed, the integrity of the BBB is restored. The data therefore provide an intellectual framework for understanding how the immune system can clear amyloid deposits from AD brains and suggest new strategies for limiting disease progression in amyloidopathies.
authors.affiliation: Michael Smith Laboratories, University of British Columbia, Vancouver, BC, Canada.
authors.forename: Dara L
authors.initials: DL
authors.lastname: Dickstein
authors.forename: Kaan E
authors.initials: KE
authors.lastname: Biron
authors.forename: Maki
authors.initials: M
authors.lastname: Ujiie
authors.forename: Cheryl G
authors.initials: CG
authors.lastname: Pfeifer
authors.forename: Andrew R
authors.initials: AR
authors.lastname: Jeffries
authors.forename: Wilfred A
authors.initials: WA
authors.lastname: Jefferies
mesh_terms: D000544:Alzheimer Disease / Q000276:immunology / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D016229:Amyloid beta-Peptides / Q000276:immunology*; D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000378:metabolism; D001812:Blood-Brain Barrier; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D017628:Microglia / Q000276:immunology; D009928:Organ Specificity; D010446:Peptide Fragments / Q000276:immunology*; D058225:Plaque, Amyloid / Q000276:immunology; D014611:Vaccination
chemical_list: D016229:Amyloid beta-Peptides; D000906:Antibodies; D010446:Peptide Fragments; C078592:amyloid beta-protein (1-40)